Kathleen Bradish’s practice focuses on antitrust matters, including mergers, litigation, and government investigations.
Kathleen originally joined the firm in 2005 and became counsel in 2014. In 2015, she joined the U.S. Department of Justice.
Most recently, she was Assistant Chief of the DOJ Antitrust Division’s International Section. In that capacity, she served as deputy chief handling the Antitrust Division’s international relations. She was responsible for presenting the enforcement views in international settings and within U.S. agencies. Kathleen also advised case teams on issues affecting cooperation with foreign antitrust enforcers, provided guidance to leadership on competition issues arising abroad affecting the United States. She supervised the Antitrust Division’s technical assistance program and trade involvement, including leading the negotiations of competition chapters in the U.S.-Mexico-Canada Agreement and in the Transatlantic Trade and Investment Partnership. Kathleen served as lead negotiator for the division’s initiative to increase international convergence on basic principles of due process.
Between 2015 and 2018, she was International Counsel in the DOJ’s Antitrust Division and led the Justice Department’s relationship with Canadian, Australian, and New Zealand antitrust authorities and worked extensively on matters involving China. She also worked on the revision of DOJ-FTC International Enforcement and Cooperation Guidelines.
Kathleen returned to the firm as a counsel in 2018.
M&A and Joint Ventures
GlaxoSmithKline in numerous matters including its multibillion-dollar three-part transaction with Novartis involving restructuring of vaccine, oncology, and consumer health businesses (GCR’s “Matter of the Year,” 2015).
Lafarge in its €40 billion combination with Holcim.
Abbott in its $6.6 billion acquisition of Solvay, including pharmaceutical, vaccines, and molecular diagnostics testing businesses.
Grupo Bimbo in its acquisition of Sara Lee’s U.S. baked goods business.
Asahi Kasei in $2.2 billion acquisition of Polypore’s energy storage unit.
3M in multiple acquisitions and joint ventures.
Several pharmaceutical companies in product acquisitions and joint ventures, including GlaxoSmithKline in its formation of the ViiV joint venture with Pfizer regarding HIV treatment research.
GlaxoSmithKline in its formation of the ViiV joint venture with Pfizer regarding HIV treatment research.
Antitrust Litigation and Investigations
Several pharmaceutical and health care services companies in conjunction with Federal Trade Commission investigations into potential anticompetitive conduct, including reviews of patent settlements.
Gilead Sciences in conjunction with putative class action alleging monopolization and unfair competition violations.
Asahi Flat Glass in federal class action price-fixing litigation, including opt-out cases.
Lafarge in federal class action price-fixing litigation.
Otis Elevator in a Second Circuit appeal of a motion to dismiss a class action price-fixing and monopolization case.
Citigroup in a DOJ investigation regarding potential anticompetitive conduct in trading of credit default swaps.
Third party in a DOJ investigation into potential anticompetitive conduct in the seed traits business.
Member, ABA Section of Antitrust Law, International Task Force
February 28, 2019
October 30, 2018
November 10, 2017
May 12, 2017
October 29, 2016
January 23, 2015
April 10, 2014
November 21, 2011
November 21, 2011